clinical trial · NCT00959647
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.·phase2·completed·n = 19
Ovarian CancerBasal Cell CarcinomaMetastatic Colorectal CancerVismodegibFOLFOXFOLFIRIBevacizumab
brief summary
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
started
Sep 3, 2009
primary completion
Jan 9, 2014
completion
Jan 9, 2014
last updated
May 8, 2026
official title
An Open-Label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol